269 related articles for article (PubMed ID: 30099860)
21. Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer.
Cheng HH; Plets M; Li H; Higano CS; Tangen CM; Agarwal N; Vogelzang NJ; Hussain M; Thompson IM; Tewari M; Yu EY
Prostate; 2018 Feb; 78(2):121-127. PubMed ID: 29105802
[TBL] [Abstract][Full Text] [Related]
22. Plasma microRNAs Predict Chemoresistance in Patients With Metastatic Breast Cancer.
Shao B; Wang X; Zhang L; Li D; Liu X; Song G; Cao H; Zhu J; Li H
Technol Cancer Res Treat; 2019 Jan; 18():1533033819828709. PubMed ID: 30786836
[TBL] [Abstract][Full Text] [Related]
23. Circulating microRNAs and therapy-associated cardiac events in HER2-positive breast cancer patients: an exploratory analysis from NeoALTTO.
Pizzamiglio S; Ciniselli CM; de Azambuja E; Agbor-Tarh D; Moreno-Aspitia A; Suter TM; Trama A; De Santis MC; De Cecco L; Iorio MV; Silvestri M; Pruneri G; Verderio P; Di Cosimo S
Breast Cancer Res Treat; 2024 Jul; 206(2):285-294. PubMed ID: 38689174
[TBL] [Abstract][Full Text] [Related]
24. miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer.
Li HY; Liang JL; Kuo YL; Lee HH; Calkins MJ; Chang HT; Lin FC; Chen YC; Hsu TI; Hsiao M; Ger LP; Lu PJ
Breast Cancer Res; 2017 Dec; 19(1):133. PubMed ID: 29258605
[TBL] [Abstract][Full Text] [Related]
25. Response Assessment With Molecular Characterization of Circulating Tumor Cells and Plasma MicroRNA Profiling in Patients With Locally Advanced Breast Cancer During Neoadjuvant Chemotherapy.
Akkiprik M; Koca S; Uğurlu MÜ; Ekren R; Peker Eyüboğlu İ; Alan Ö; Erzik C; Güllü Amuran G; Telli TA; Güllüoğlu MB; Sezerman U; Yumuk PF
Clin Breast Cancer; 2020 Aug; 20(4):332-343.e3. PubMed ID: 32201164
[TBL] [Abstract][Full Text] [Related]
26. Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy.
Di Cosimo S; Appierto V; Pizzamiglio S; Silvestri M; Baselga J; Piccart M; Huober J; Izquierdo M; de la Pena L; Hilbers FS; de Azambuja E; Untch M; Pusztai L; Pritchard K; Nuciforo P; Vincent-Salomon A; Symmans F; Apolone G; de Braud FG; Iorio MV; Verderio P; Daidone MG
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32085669
[TBL] [Abstract][Full Text] [Related]
27. Circulating Exosomal microRNAs as Predictive Biomarkers of Neoadjuvant Chemotherapy Response in Breast Cancer.
Todorova VK; Byrum SD; Gies AJ; Haynie C; Smith H; Reyna NS; Makhoul I
Curr Oncol; 2022 Jan; 29(2):613-630. PubMed ID: 35200555
[TBL] [Abstract][Full Text] [Related]
28. Correlation of circulating pro-angiogenic miRNAs with cardiotoxicity induced by epirubicin/cyclophosphamide followed by docetaxel in patients with breast cancer.
Qin X; Chang F; Wang Z; Jiang W
Cancer Biomark; 2018; 23(4):473-484. PubMed ID: 30452398
[TBL] [Abstract][Full Text] [Related]
29. A circulating miRNA signature as a diagnostic biomarker for non-invasive early detection of breast cancer.
Zhang L; Xu Y; Jin X; Wang Z; Wu Y; Zhao D; Chen G; Li D; Wang X; Cao H; Xie Y; Liang Z
Breast Cancer Res Treat; 2015 Nov; 154(2):423-34. PubMed ID: 26476723
[TBL] [Abstract][Full Text] [Related]
30. Circulating microRNAs in the early prediction of disease recurrence in primary breast cancer.
Papadaki C; Stratigos M; Markakis G; Spiliotaki M; Mastrostamatis G; Nikolaou C; Mavroudis D; Agelaki S
Breast Cancer Res; 2018 Jul; 20(1):72. PubMed ID: 29996899
[TBL] [Abstract][Full Text] [Related]
31. Prognostic Value of a BCSC-associated MicroRNA Signature in Hormone Receptor-Positive HER2-Negative Breast Cancer.
Gong C; Tan W; Chen K; You N; Zhu S; Liang G; Xie X; Li Q; Zeng Y; Ouyang N; Li Z; Zeng M; Zhuang S; Lau WY; Liu Q; Yin D; Wang X; Su F; Song E
EBioMedicine; 2016 Sep; 11():199-209. PubMed ID: 27566954
[TBL] [Abstract][Full Text] [Related]
32. Evaluating the Role of Circulating MicroRNAs to Aid Therapeutic Decision Making for Neoadjuvant Chemotherapy in Breast Cancer: A Prospective, Multicenter Clinical Trial.
Davey MG; Casey MC; McGuire A; Waldron RM; Paganga M; Holian E; Newell J; Heneghan HM; McDermott AM; Keane MM; Lowery AJ; Miller N; Kerin MJ
Ann Surg; 2022 Nov; 276(5):905-912. PubMed ID: 35876391
[TBL] [Abstract][Full Text] [Related]
33. Serum microRNA-21 expression as a prognostic and therapeutic biomarker for breast cancer patients.
Yadav P; Mirza M; Nandi K; Jain SK; Kaza RC; Khurana N; Ray PC; Saxena A
Tumour Biol; 2016 Nov; 37(11):15275-15282. PubMed ID: 27696295
[TBL] [Abstract][Full Text] [Related]
34. Whole blood microRNAs as potential biomarkers in post-operative early breast cancer patients.
Alunni-Fabbroni M; Majunke L; Trapp EK; Tzschaschel M; Mahner S; Fasching PA; Fehm T; Schneeweiss A; Beck T; Lorenz R; Friedl TWP; Janni W; Rack B;
BMC Cancer; 2018 Feb; 18(1):141. PubMed ID: 29409452
[TBL] [Abstract][Full Text] [Related]
35. Identification of microRNA biomarkers in the blood of breast cancer patients based on microRNA profiling.
Zhang K; Wang YW; Wang YY; Song Y; Zhu J; Si PC; Ma R
Gene; 2017 Jul; 619():10-20. PubMed ID: 28359916
[TBL] [Abstract][Full Text] [Related]
36. Identification of the plasma total cfDNA level before and after chemotherapy as an indicator of the neoadjuvant chemotherapy response in locally advanced breast cancer.
Ma G; Wang J; Huang H; Han X; Xu J; Veeramootoo JS; Xia T; Wang S
Cancer Med; 2020 Apr; 9(7):2271-2282. PubMed ID: 32017472
[TBL] [Abstract][Full Text] [Related]
37. Association of microRNAs and pathologic response to preoperative chemotherapy in triple negative breast cancer: preliminary report.
Kolacinska A; Morawiec J; Fendler W; Malachowska B; Morawiec Z; Szemraj J; Pawlowska Z; Chowdhury D; Choi YE; Kubiak R; Pakula L; Zawlik I
Mol Biol Rep; 2014 May; 41(5):2851-7. PubMed ID: 24469723
[TBL] [Abstract][Full Text] [Related]
38. Exosomal miRNA profile as complementary tool in the diagnostic and prediction of treatment response in localized breast cancer under neoadjuvant chemotherapy.
Rodríguez-Martínez A; de Miguel-Pérez D; Ortega FG; García-Puche JL; Robles-Fernández I; Exposito J; Martorell-Marugan J; Carmona-Sáez P; Garrido-Navas MDC; Rolfo C; Ilyine H; Lorente JA; Legueren M; Serrano MJ
Breast Cancer Res; 2019 Feb; 21(1):21. PubMed ID: 30728048
[TBL] [Abstract][Full Text] [Related]
39. Expression of micrornas in molecular genetic breast cancer subtypes.
Kolesnikov NN; Veryaskina YA; Titov SE; Rodionov VV; Gening TP; Abakumova TV; Kometova VV; Torosyan MK; Zhimulev IF
Cancer Treat Res Commun; 2019; 20():100026. PubMed ID: 31255253
[TBL] [Abstract][Full Text] [Related]
40. Plasma miR-21, miR-155, miR-10b, and Let-7a as the potential biomarkers for the monitoring of breast cancer patients.
Khalighfard S; Alizadeh AM; Irani S; Omranipour R
Sci Rep; 2018 Dec; 8(1):17981. PubMed ID: 30568292
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]